Source: Annual Congress 2009 - New aspects of inhalation therapy
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Alaboud, K. Assi, H. Chrystyn (Bradford, Huddersfield, United Kingdom). Dose emission from a formoterol aerolizer is dependent on inhalation flow and volume. Eur Respir J 2009; 34: Suppl. 53, 2038

Member's Comments

No comment yet.

Related content which might interest you: Tiotropium dose emission is influenced by the inhalation flow and the recommended two inhalations for each dose Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005 In vitro dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 Delivered dose and fine particle dose of aclidinium bromide 200 µg via the Genuair® inhaler are independent of flow rate within the working range of the device Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Effect of sequential nebulised salbutamol therapy on peak expiratory flow rate Source: Eur Respir J 2005; 26: Suppl. 49, 507s Year: 2005 Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers Source: Eur Respir J 2001; 18: 780-783 Year: 2001 Flutide™ Diskus™ less consistent than Pulmicort® Turbuhaler® with respect to in vitro fine particle dose proportionality Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Different inhalation volumes do not impact on the aerodynamics of aclidinium bromide delivered using the Genuair® inhaler Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Effect of changes in peak inspiratory flow on the dose of salbutamol delivered by nebulizers under simulated conditions Source: International Congress 2018 – What’s new in lung function and exercise assessment in COPD? Year: 2018 In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 A pMDI formulation of levosalbutamol produces an equivalent bronchodilator response as racemic salbutamol at half the dose Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005 Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Peak inspiratory flow rate and the slope of the inhalation profile in dry powder inhalers (DPI) Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001 Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019 Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler® Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Pressurised metered dose inhalers (pMDIs) with integrated flow rate guidance. Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Two-tone trainer maintains a slow inhalation rate when using a metered dose inhaler (MDI) Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002 Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Source: Eur Respir J 2003; 21: 86-94 Year: 2003 Dose- and exposure-response modeling to support development of formoterol fumarate (FF) metered dose inhaler (MDI) for COPD Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010